Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NRx Defense Systems is a wholly-owned subsidiary of NRx Pharmaceuticals focused on developing medical countermeasures for the U.S. Department of Defense and other government agencies. The company leverages its parent's expertise in NMDA receptor modulation to develop treatments for organophosphate-induced brain injury and chemical warfare agent exposure. Its primary focus is the development of NRX-101 and related compounds as potential antidotes for nerve agents. Additionally, the company explores applications for its therapeutic candidates in treating sepsis-induced respiratory failure and other biodefense-related medical needs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NRx Defense Systems.